Alterity Therapeutics Ltd represents values of innovation, scientific rigor, and collaboration in the field of neurodegenerative diseases. The company's corporate philosophy emphasizes a patient-centric approach, aiming to develop transformative treatments for disorders like Parkinson's and Alzheimer's disease. Alterity Therapeutics fosters a culture of excellence and ethical behavior, prioritizing the well-being of patients and supporting their families. By investing in cutting-edge research and partnering with experts, Alterity Therapeutics seeks to provide novel therapies that can improve the quality of life for individuals affected by these devastating conditions.

Alterity Therapeutics Ltd is primarily present in Australia and the United States.

Alterity Therapeutics Ltd, a leading biotechnology company, has achieved several significant milestones in its journey. The company has successfully developed innovative therapies and drug candidates, revolutionizing the treatment of neurological disorders. Alterity Therapeutics Ltd has advanced its flagship drug, PBT434, through multiple clinical trials, demonstrating promising results in treating Parkinson's and other neurodegenerative diseases. The company has also secured valuable partnerships with renowned institutions and researchers, further validating its scientific approach. Leveraging its expertise in targeting neurodegeneration, Alterity Therapeutics Ltd continues to make groundbreaking progress in improving patient outcomes and has garnered recognition from the scientific and investor community alike.

Alterity Therapeutics Ltd is a biotechnology company focused on the development of novel therapies for the treatment of neurodegenerative diseases. Founded in 1997, Alterity has been dedicated to researching and developing drug candidates targeting Parkinson's and Alzheimer's diseases. The company's lead candidate, PBT2, has shown promising results in pre-clinical and clinical trials, demonstrating its potential to treat neurodegeneration by reducing brain metal imbalances. With an experienced team and strategic partnerships, Alterity Therapeutics Ltd is committed to advancing their innovative therapies to address the growing need for effective treatments in the field of neurodegenerative diseases.

The main competitors of Alterity Therapeutics Ltd in the market include major pharmaceutical companies such as Biogen, Pfizer, and Novartis. These companies also focus on developing treatments and therapies for neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. Alterity Therapeutics Ltd competes with these industry leaders in terms of research, development, and commercialization of innovative drug candidates targeting neurodegenerative disorders.

Alterity Therapeutics Ltd is primarily active in the pharmaceutical and biotechnology industries. As a leading company, Alterity Therapeutics specializes in developing innovative therapies for neurodegenerative diseases, particularly Parkinson's and Alzheimer's. With a focus on altering the course of these debilitating conditions, Alterity Therapeutics conducts extensive research and collaborates with healthcare professionals and industry experts to bring about groundbreaking treatments. By leveraging its expertise in drug development and neurology, Alterity Therapeutics continues to make significant contributions to the field of healthcare, offering hope and improving the lives of patients worldwide.

Alterity Therapeutics Ltd operates as a biotechnology company. The business model of Alterity Therapeutics is focused on the development and commercialization of novel therapeutics for neurodegenerative diseases. The company primarily specializes in the research and development of drugs targeting Parkinson's and Alzheimer's diseases. Alterity Therapeutics aims to identify and develop small molecules that can effectively treat neurological disorders by targeting misfolded proteins, specifically alpha-synuclein and tau. By addressing these protein abnormalities, Alterity Therapeutics seeks to provide innovative treatment options for patients suffering from neurodegenerative diseases.

Alterity Therapeutics KGV ir -0,58.

Alterity Therapeutics KUV ir 41,10.

AlleAktien kvalitātes vērtējums Alterity Therapeutics ir 4/10.

Alterity Therapeutics apgrozījums ir 268 420,00 AUD.

Alterity Therapeutics peļņa ir -19,12 milj. AUD.

Alterity Therapeutics Ltd is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company is headquartered in Australia and has a branch in the USA. The business model of Alterity Therapeutics is based on the discovery, development, and commercialization of therapies for diseases such as Parkinson's, Alzheimer's, and multiple sclerosis. The company has a proprietary technology platform called "Stellate Therapies" that is based on the discovery of novel compounds capable of detecting and eliminating abnormally folded proteins in the brain. Alterity Therapeutics is also proud to have a strong pipeline of product candidates. Their leading candidate is currently ATH434, which is in a phase II study for the treatment of Parkinson's. The drug aims to break down the protein alpha-synuclein, which occurs in abnormal amounts in Parkinson's patients, slowing down the progression of the disease. In addition to ATH434, the company is working on the development of other Stellate candidates, including ATH554 and ATH555, which are in preclinical studies. These candidates target other protein-related diseases such as Alzheimer's and ALS. The business model of Alterity Therapeutics is not only limited to the development of new therapies but also to collaborating with other companies. The company has partnerships with leading pharmaceutical companies such as Takeda, Sanofi, and Axovant Sciences to work together on therapy development. Alterity Therapeutics also has a research and development department focused on advancing the company's knowledge and technology platform. It is also determined to enter into new partnerships to explore further opportunities for therapy development and commercialization. Overall, the business model of Alterity Therapeutics is aimed at giving patients with neurodegenerative diseases new hope. Through the development of innovative therapies and collaboration with other companies, the goal is to improve the lives of people affected by these diseases.

Alterity Therapeutics izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Alterity Therapeutics vai uzņēmums nedod dividendes.

Alterity Therapeutics ISIN ir AU0000043945.

Alterity Therapeutics WKN ir A2PHDZ.

Alterity Therapeutics simbols ir ATH.AX.

Pēdējo 12 mēnešu laikā Alterity Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Alterity Therapeutics plāno maksāt dividendes 0 AUD apmērā.

Alterity Therapeutics pašreizējā dividendu rentabilitāte ir .

Alterity Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Alterity Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Alterity Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Alterity Therapeutics apmērā 0 AUD, kas tika izmaksāta 22.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 22.09.2024..

Pēdējās dividendes izmaksa notika 22.09.2024..

Gadā 2023, Alterity Therapeutics izmaksāja 0 AUD dividendes.

Alterity Therapeutics dividendes tiek izmaksātas AUD.